Thiogenesis Therapeutics Corp.
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated ste… Read more
Thiogenesis Therapeutics Corp. (TTI) - Total Liabilities
Latest total liabilities as of September 2025: CA$1.47 Million CAD
Based on the latest financial reports, Thiogenesis Therapeutics Corp. (TTI) has total liabilities worth CA$1.47 Million CAD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Thiogenesis Therapeutics Corp. - Total Liabilities Trend (2019–2024)
This chart illustrates how Thiogenesis Therapeutics Corp.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Thiogenesis Therapeutics Corp. Competitors by Total Liabilities
The table below lists competitors of Thiogenesis Therapeutics Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Charoong Thai Wire and Cable Public Company Limited
BK:CTW
|
Thailand | ฿1.75 Billion |
|
VentriPoint Diagnostics Ltd
PINK:VPTDF
|
USA | $5.03 Million |
|
Aimflex Bhd
KLSE:0209
|
Malaysia | RM18.32 Million |
|
Keum Kang Steel Co. Ltd
KQ:053260
|
Korea | ₩21.31 Billion |
|
Trio-Tech International
NYSE MKT:TRT
|
USA | $13.99 Million |
|
IFCA MSC Bhd
KLSE:0023
|
Malaysia | RM32.14 Million |
|
Gold Hydrogen Ltd
AU:GHY
|
Australia | AU$1.13 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Thiogenesis Therapeutics Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.68 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Thiogenesis Therapeutics Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Thiogenesis Therapeutics Corp. (2019–2024)
The table below shows the annual total liabilities of Thiogenesis Therapeutics Corp. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$557.88K | -67.43% |
| 2023-12-31 | CA$1.71 Million | +457.66% |
| 2022-12-31 | CA$307.15K | -91.21% |
| 2021-12-31 | CA$3.49 Million | +5436.50% |
| 2020-12-31 | CA$63.08K | +416.03% |
| 2019-12-31 | CA$12.22K | -- |